Capturing 1% of the ovarian cancer monitoring market would generate $97.5 million in annual revenues for Arrayit through the manufacture and sale of 150,000 OvaDx® tests at $650 per test.
:) Arrayit Corporation provides the market’s first large panel research test for ovarian cancer samples. OvaDx® RUO is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® RUO indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Arrayit offers OvaDx® RUO for research purposes only to advance the forefront of ovarian cancer biology. OvaDx® RUO can be used to analyze samples derived from different tumor types and stages, the effectiveness of experimental chemotherapies, biomarker profiles in breast cancer and other epithelial cancers samples, studies of benign gynecological tumors, the effectiveness of ovarian cancer lead compounds, and for comparative research studies of existing tests including CA-125, OVA1®, and transvaginal ultrasound. The OvaDx® Ovarian Cancer Research Complete Platform (Cat. ORUOCP) includes a fluorescence scanner, reaction and processing hardware, quantification software, and 100 OvaDx® RUO kits.
News 
Market Data 
Discover 
